In the OVHIPEC-1 trial, patients with homologous recombination deficiency (HRD) without a pathogenic BRCA1/2 mutation benefited more from HIPEC in terms of overall and progression-free survival. The gene discussed is BRCA1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.